12月3日，英诺特跌2.24%，成交额6722.98万元。两融数据显示，当日英诺特获融资买入额660.86万 元，融资偿还735.21万元，融资净买入-74.35万元。截至12月3日，英诺特融资融券余额合计1.84亿元。 融资方面，英诺特当日融资买入660.86万元。当前融资余额1.84亿元，占流通市值的8.11%，融资余额 低于近一年10%分位水平，处于低位。 机构持仓方面，截止2025年9月30日，英诺特十大流通股东中，医疗器械ETF（159883）位居第九大流 通股东，持股49.80万股，为新进股东。 责任编辑：小浪快报 资料显示，北京英诺特生物技术股份有限公司位于北京市丰台区海鹰路1号院6号楼1层2层、2号楼7层， 成立日期2006年2月6日，上市日期2022年7月28日，公司主营业务涉及POCT快速诊断产品研发、生产 和销售。主营业务收入构成为：呼吸道系列96.49%，其他试剂系列2.99%，优生优育系列0.51%。 截至9月30日，英诺特股东户数8037.00，较上期增加10.57%；人均流通股8627股，较上期减少8.86%。 2025年1月-9月，英诺特实现营业收入3.30亿元，同比减少36. ...

Core Viewpoint - Beijing Innotech Biotechnology Co., Ltd. has recently obtained a new product qualification, enhancing its market expansion capabilities and core competitiveness [2][3]. Group 1: Recent Qualification - The company has acquired one new product qualification, which is intended for in vitro qualitative detection of Helicobacter pylori antigens in human fecal samples. This product is suitable for both professional medical personnel in medical institutions and for consumer self-testing [2]. Group 2: Impact on the Company - The acquisition of this qualification broadens the range of products offered by the company, thereby improving its market expansion capabilities and core competitiveness [3].

证券代码：688253 证券简称：英诺特 公告编号：2025-060 北京英诺特生物技术股份有限公司关于公司近期获 得资质情况的自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、公司近期获得资质的基本情况 北京英诺特生物技术股份有限公司（以下简称"公司"）近期新取得产品资 质 1 项，具体情况如下表所示： | 北京英诺特生物技术 | 幽门螺杆菌抗原检测试 | 国械注准 | 2025/11/25 | 2030/11/24 | | --- | --- | --- | --- | --- | | 获批主体 股份有限公司 | 产品名称 剂盒（乳胶法） | 注册证号（备案号） 20253402376 | 发证日期 | 有效期至 | 本产品预期用途为用于体外定性检测人粪便样本中幽门螺杆菌抗原，既适用 于专业医务人员在医疗单位进行人粪便样本中的幽门螺杆菌抗原检测，也适用于 消费者自测。 上述资质的取得，拓宽了公司产品的种类，进一步提高了公司的市场拓展能 力及核心竞争力。 三、风险提示 上述产品的实际销售受到市场需求、市场 ...

上述资质的取得，拓宽了公司产品的种类，进一步提高了公司的市场拓展能力及核心竞争力。 格隆汇12月1日丨英诺特(688253.SH)公布,公司近期新取得产品资质1项。产品名称：幽门螺杆菌抗原检 测试剂盒（乳胶法），注册证号（备案号）：国械注准20253402376。 本产品预期用途为用于体外定性检测人粪便样本中幽门螺杆菌抗原，既适用于专业医务人员在医疗单位 进行人粪便样本中的幽门螺杆菌抗原检测，也适用于消费者自测。 ...

Core Viewpoint - InnoTech (688253.SH) has recently obtained a new product qualification for a Helicobacter pylori antigen detection kit, enhancing its product range and market competitiveness [1] Product Qualification - The newly acquired product is a Helicobacter pylori antigen detection kit (latex method) with registration number 20253402376 [1] - The intended use of this product is for the qualitative detection of Helicobacter pylori antigen in human fecal samples, suitable for both professional medical personnel in healthcare settings and for consumer self-testing [1] Market Expansion - The acquisition of this qualification broadens the company's product offerings, thereby improving its market expansion capabilities and core competitiveness [1]

Core Viewpoint - InnoTech (688253) has recently obtained a new product qualification for a Helicobacter pylori antigen test kit (latex method), which is intended for in vitro qualitative detection of Helicobacter pylori antigen in human fecal samples [1] Group 1 - The product is suitable for use by healthcare professionals in medical institutions for detecting Helicobacter pylori antigen in human fecal samples [1] - The test kit is also designed for consumer self-testing [1]

英诺特公告称，公司近期新取得1项产品资质，即幽门螺杆菌抗原检测试剂盒（乳胶法），注册证号为 国械注准20253402376，发证日期为2025年11月25日，有效期至2030年11月24日。该产品可用于体外定 性检测人粪便样本中幽门螺杆菌抗原，适用于专业医务人员检测和消费者自测。此次资质拓宽了公司产 品种类，提高市场拓展及核心竞争力，但产品实际销售受多种因素影响，对业绩影响尚无法预测。 ...

Investment Rating - The report maintains an "Overweight" rating for the in vitro diagnostics (IVD) industry [6][54]. Core Viewpoints - The IVD market is expected to benefit from a recent policy initiative aimed at enhancing the adaptability of supply and demand for consumer goods, with a focus on high-end medical devices and efficient IVD equipment [5][53]. - The domestic biochemical diagnostics sector has largely overcome reliance on foreign technologies, indicating a completed process of localization [6][54]. - The report emphasizes the shift towards home health management, moving from a treatment-centered to a prevention-centered approach, which is expected to create a trillion-yuan integrated market [5][53]. Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 2.67%, with the IVD sector increasing by 2.63% during the week [2][12]. - The IVD sector's current PE ratio is 39.84X, with a PB ratio of 1.85X, reflecting a slight increase from the previous week [4][33]. Company Performance - Notable performers in the medical services sector include Haobio (+14.3%), Shuoshi Biological (+13.6%), and Innotech (+13.3%) [3][29]. - Underperformers include *ST Dongyang (-7.2%) and New Industry (-5.7%) [3][29]. Investment Recommendations - The report suggests focusing on companies in the IVD sector that cater to home consumption scenarios, such as Shengxiang Biological and Sannuo Biological [5][54]. - It highlights the importance of monitoring the growth potential in immunodiagnostics, particularly in chemiluminescence and molecular diagnostics like PCR [6][54].

Core Points - The Shanghai Composite Index closed at 3864.18 points, slightly down by 0.15%, with a total trading volume of 1.79719 trillion yuan [1] - A total of 46 A-shares have surpassed their annual moving average, with notable stocks showing significant deviation rates [1] Stock Performance - The stocks with the highest deviation rates from their annual moving averages include: - Haiwang Biological (9.74%) - Hongmian Co. (8.84%) - Xueqi Electric (8.82%) [1] - Other stocks that have just crossed their annual moving averages with lower deviation rates include: - Wanhua Chemical - Youfang Technology - Shenzhen Gas [1] Trading Data - The trading data for stocks that broke through the annual moving average includes: - Haiwang Biological: Today's change +10.20%, turnover rate 3.55%, latest price 2.81 yuan - Hongmian Co.: Today's change +9.91%, turnover rate 9.39%, latest price 3.55 yuan - Xueqi Electric: Today's change +10.04%, turnover rate 12.98%, latest price 15.02 yuan [1]

Group 1 - The demand for flu-related medications is rising significantly as the flu season approaches, with several stocks in the sector experiencing price surges [1] - Notable stocks that have reached their daily limit include Jindike, Peking University Medicine, and Te Yi Pharmaceutical, among others [1] - Data from Alibaba Health indicates a more than 500% week-on-week increase in the number of people purchasing antiviral flu medications, with Mabalosavir showing a remarkable over 600% increase [1] Group 2 - Experts warn that the H3N2 strain circulating this year is different from previous years, leading to lower immunity in the population and increased transmission risk [2] - The flu virus is known to undergo antigenic drift, but current strains are still within seasonal levels and do not indicate a stronger evolution of the virus [2] Group 3 - Companies are actively ensuring the supply of flu medications and vaccines in response to rising demand [3] - Dongyang Sunshine, a major supplier of Oseltamivir, reports comprehensive coverage of its products across hospitals, pharmacies, and online platforms, maintaining sufficient inventory [3] - Hualan Biological has noted a significant increase in demand for flu vaccines since October, with plans to enhance market supply and ensure timely delivery through cold chain logistics [3]